A2i Therapeutics

About

Funding history · 1 round · — total

Q&A

What is A2i Therapeutics developing?

A2i Therapeutics is developing novel small-molecule immuno-oncology agents.

When was A2i Therapeutics founded?

A2i Therapeutics was founded in November 2020.

How many employees does A2i Therapeutics have?

A2i Therapeutics has 1-10 employees.

What is the primary sector of A2i Therapeutics?

A2i Therapeutics' primary sector is Health Tech & Life Sciences.

Which companies formed A2i Therapeutics as a joint venture?

A2i Therapeutics was formed as a joint venture between FutuRx, an Israeli biotechnology incubator, and Atomwise, a US-based company using AI for small-molecule drug discovery.

What is the purpose of the partnership between A2i Therapeutics and Atomwise?

The partnership leverages Atomwise's AI platform to target a key protein involved in controlling the innate immune response, which is a potential immuno-oncology target.

Which investors participated in A2i Therapeutics' funding round in November 2020?

RMGP Biopharma Investment Fund and FutuRx participated in A2i Therapeutics' funding round in November 2020.

What is A2i Therapeutics' current funding stage?

A2i Therapeutics is currently in the Seed funding stage.

Sectors & technology

Tags